MATEON THERAPEUTICS, INC. COMMON STOCK PURCHASE WARRANT AUGUST 7, 2020Warrant Agreement • August 13th, 2020 • Mateon Therapeutics Inc • Pharmaceutical preparations • California
Contract Type FiledAugust 13th, 2020 Company Industry JurisdictionTHIS COMMON STOCK PURCHASE WARRANT (this “Warrant”) of Mateon Therapeutics, Inc., a corporation duly organized and validly existing under the laws of Delaware (the “Company”), is issued to the Holder (as defined below) as part of a unit purchased by the Holder from the Company pursuant to which the Holder is also purchasing from the Company notes convertible into shares of its Common Stock, $0.01 par value per share (the “Common Stock”), shares of the common stock of EdgePoint AI, Inc. (“EdgePoint”), a subsidiary of the Company wholly-owned by it, warrants, including this Warrant, to purchase shares of Common Stock and warrants to purchase EdgePoint’s common stock, (the “Offering”).
SUBSCRIPTION AGREEMENT AND INVESTMENT LETTERSubscription Agreement • August 13th, 2020 • Mateon Therapeutics Inc • Pharmaceutical preparations • California
Contract Type FiledAugust 13th, 2020 Company Industry JurisdictionThis Subscription Agreement (this “Subscription Agreement”) is being delivered to the purchaser identified on the signature page to this Agreement (the “Undersigned” or “Subscriber”) in connection with its investment in the securities of Mateon Therapeutics, Inc., a Delaware corporation (the “Company”). The Company is conducting a private placement (the “Offering”) of a minimum of 40 and a maximum of 100 Units (the “Units”), each of which consists of 25,000 shares of the Common Stock of the Company’s wholly owned subsidiary called EdgePoint AI, Inc., a Delaware corporation (“EdgePoint”), and one note issued by the Company (a “Note” and collectively, the “Notes”), in the principal amount of $25,000.00, bearing annual interest at the rate of 16%. Each Note will be convertible into up to 25,000 shares of EdgePoint’s Common Stock (conversion price $1.00 per share) or up to 138,889 shares of Mateon’s Common Stock (conversion price approximately $0.18 per share), subject to applicable anti d
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • August 13th, 2020 • Mateon Therapeutics Inc • Pharmaceutical preparations • Delaware
Contract Type FiledAugust 13th, 2020 Company Industry JurisdictionThis Registration Rights Agreement (this “Agreement”) is made and entered into as of August 7, 2020, by and among Mateon Therapeutics, Inc. (the “Company”), a Delaware corporation with offices at 20397 Agoura Road, Suite 107, Agoura Hills, California 91301, and the investors signatories hereto (each a “Purchaser” and collectively, the “Purchasers”). This Agreement is made pursuant to the Subscription Agreement and Investment Letter, dated as of the date hereof, executed by each of the Purchasers and the Company (the “Subscription Agreement”).
February 25, 2020Engagement Agreement • August 13th, 2020 • Mateon Therapeutics Inc • Pharmaceutical preparations • New York
Contract Type FiledAugust 13th, 2020 Company Industry JurisdictionThis letter will confirm the understanding and agreement (the “Agreement”) between J H Darbie & Co., Inc. (“JHD”), and Mateon Therapeutics, Inc. (the “Company”), as follows: